Topological modification of interleukin-2 and its application as a drug for autoimmune diseases

By topologically modifying IL-2 to form ring-shaped and corrohydrogen structures, the problem of short half-life of the existing IL-2 dosage form is solved, long-term immune regulation of interleukin-2 is achieved, and the effect and safety of autoimmune disease treatment is improved. sex.

CN117003852BActive Publication Date: 2024-11-05BEIJING TUOYINHESHENG TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310827760.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-07-07
Filing Date
2023-07-07
Publication Date
2024-11-05
Estimated Expiration
2043-07-07

AI Technical Summary

Technical Problem

The existing interleukin-2 (IL-2) dosage forms have short half-life, making it difficult to achieve long-term and stable immune regulation, and cannot meet the long-term drug needs of patients with autoimmune diseases.

Method used

By topologically modifying IL-2, interleukin-2 of circular and corrugated structures is formed, enhancing its targeting and stability, forming a circular structure by connecting the N-terminal and C-terminal, forming a corrugated structure by suppressing tumor The factor p53dim(X) forms a dimer, which improves its half-life and affinity with the receptor.

Benefits of technology

Topologically modified IL-2 can significantly improve half-life and stability, reduce dose and drug administration, improve treatment safety, effectively activate Treg cells, inhibit pathogenic Tfh and Th17 cells, improve immune imbalance, and is suitable for autoimmune diseases. long-term treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117003852B_ABST
    Figure CN117003852B_ABST
Patent Text Reader

Abstract

The present invention discloses the topological modification of interleukin-2 and its application as a drug for autoimmune diseases. The present invention performs topological modification on interleukin-2 to obtain interleukin-2 with a cyclic or catenane topological structure that activates Treg in a targeted manner. The interleukin-2 with a cyclic or catenane structure does not change its affinity with the receptor, and can prolong the half-life of the drug, enhance stability, reduce the dosage and number of medications for long-term use, and exert the effect of suppressing immunity. The interleukin-2 topologically modified protein of the present invention is a long-acting immunosuppressant, which is beneficial for treating a variety of autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biopharmaceuticals, and specifically relates to topologically modified interleukin-2 and its application in the treatment of autoimmune diseases. Background Art

[0002] Interleukin-2 (IL-2) is a multifunctional T cell growth factor that promotes the proliferation of conventional helper T cells (Tcon), effector T lymphocytes (Teff) and CD8 + T cell proliferation is crucial. High doses of IL-2 are used to treat tumors and enhance the immunogenicity of cancer patients; low doses of IL-2 can selectively stimulate the proliferation of regulatory T cells (Treg), inhibit the differentiation of Tcon and Teff cells, and effectively improve the immune homeostasis of patients with systemic lupus erythematosus (SLE). After low-dose IL-2 treatment, the patient's clinical symptoms such as rash, fever, arthritis, nephritis, anti-dsDNA titer and complement level were significantly improved. At the same time, the patient's Treg level increased, and the inhibitory function was enhanced, the pathogenic Tfh and Th17 cell levels decreased, the immune imbalance improved, and the SLEDAI score reflecting the severity of the disease decreased significantly. However, patients with autoimmune diseases often require long-term medication. The currently used IL-2 dosage form is not designed for low-dose IL-2 therapy for autoimmune diseases and has a short half-life. For the above reasons, there is a need for IL-2 biologics with improved pharmacokinetics and long-lasting efficacy. Summary of the invention

[0003] In order to solve the above problems, the object of the present invention is to provide a long-acting interleukin-2 targeting regulatory T cells (Treg) and its application in treating autoimmune diseases.

[0004] To achieve the above technical objectives, the present invention has topologically modified interleukin-2 (IL-2) to provide a cyclic and catenane topological structure that can enable interleukin-2 to activate Treg in a targeted manner. The structures of the cyclic interleukin-2 and catenane interleukin-2 obtained by topological modification in the present invention are shown in Figure 1 , as described in (1) and (2) below:

[0005] (1) Circular remodeled protein c-IL-2: The N-terminus and C-terminus of interleukin-2 are connected to form interleukin-2 with a ring structure;

[0006] (2) Catenane-modified protein cat-(X-IL-2): IL-2 is fused with protein entanglement motifs that can form dimers, such as the tumor suppressor factor p53dim(X). Through the formation of intermolecular entanglement dimers and a closed ring structure through protein entanglement motifs such as the tumor suppressor factor p53dim(X), an X-IL-2 dimer with a catenane structure is obtained.

[0007] The construction of cyclic interleukin-2 and catenane interleukin-2 can refer to the methods described in Chinese invention patents ZL.201510593863.9, ZL.2019113736.3.5, ZL.202010436910.X, etc. The protein coupling reaction pair is connected to the N-terminus and C-terminus of interleukin-2, so that the expressed protein precursor sequence undergoes coupling reaction in the cell to achieve cyclization, and obtains interleukin-2 with a ring structure. The protein coupling reaction pair can be composed of the C-terminal part (IntC) and the N-terminal part (IntN) of the isolated intein, or it can be composed of a spy tag and a spy catcher. Furthermore, IL-2 was fused with a protein entanglement motif capable of forming a dimer, and a protein coupling reaction pair was connected to the N-terminus and C-terminus of the fusion expression fragment. The expressed protein precursor sequence formed a dimer and closed the ring in the cell to obtain an interleukin-2 dimer with a catenane structure.

[0008] In an embodiment of the present invention, the amino acid sequence of human interleukin-2 modified into a ring structure is shown in SEQ ID No: 1 in the sequence listing; the human interleukin-2 modified into a catenane structure is composed of two identical rings, and the amino acid sequence of each ring is shown in SEQ ID No: 2 in the sequence listing.

[0009] The present invention also provides the use of the above-mentioned IL-2 topologically modified protein in the preparation of drugs for treating immune-related diseases, which can be used for safe, effective, single-shot and long-term treatment of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, etc., and can also be used for other diseases with the same pathogenesis, including organ transplant rejection, graft-versus-host disease, dermatomyositis, multiple sclerosis, etc., as well as drug treatments for tumors, viral infections, and immunodeficiency diseases.

[0010] The pharmaceutical composition containing the above-mentioned IL-2 topologically modified protein is also within the scope of protection of the present invention. The pharmaceutical composition can be in the form of injection, tablet, powder, capsule, film, suppository, etc., and can also be added with one or more pharmaceutically acceptable carriers or excipients. The carrier or excipient includes conventional diluents, excipients, fillers, binders, disintegrants, surfactants, absorption promoters, adsorption carriers, etc. in the pharmaceutical field.

[0011] The IL-2 topologically modified protein obtained by the present invention has the characteristics of uniform chemical properties and biological activities, and has the following technical advantages compared with existing research drugs (natural IL-2 or recombinant IL-2):

[0012] The present invention improves the half-life of IL-2, enhances the stability and affinity of IL-2 to the receptor, reduces the dosage and administration frequency of IL-2 for long-term use, and improves the safety of IL-2 treatment by topologically modifying IL-2 while retaining the targeting property of IL-2. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 The gene cassettes of cyclic interleukin-2 (A) and catenoid interleukin-2 (B) and their simulated protein structures are shown. The recombinant plasmids of cyclic and catenoid interleukin-2 were transferred into E. coli Origami (DE3), and through induced expression, the separated intein closed the ring in the cell to obtain interleukin-2 with a specific topological structure. The figure shows the expression products of different topological structures and their relationship with receptors IL-2Rα, IL-2Rβ, and IL-2Rγ.

[0014] Figure 2 The figure shows the characterization of the properties of cyclic interleukin-2 (c-IL-2) and catenoid interleukin-2 (cat-(X-IL-2)), where: (A) is SDS-PAGE characterization. Since the closed-ring protein is more compact and migrates faster than the linear protein, it has a smaller apparent molecular weight; (B) is size exclusion chromatography characterization. The hydration radius of catenoid interleukin-2 is slightly larger than that of the cyclic molecule, so the retention volume is smaller, which is in line with expectations; (C) is LC-MS characterization, and the actual molecular weight of the protein is verified; (D) is circular dichroism characterization, which proves that the cyclic and catenoid isomers have secondary structures similar to the wild type.

[0015] Figure 3 Shown are the half-lives of wild-type interleukin-2 (wt-IL-2), cyclic interleukin-2 (c-IL-2), and catene interleukin-2 (cat-(X-IL-2)). The half-lives of c-IL-2 and cat-(X-IL-2) are significantly longer than those of wt-IL-2.

[0016] Figure 4 The affinity of c-IL-2 and cat-(X-IL-2) for IL-2Rα and IL-2Rβ was characterized. The K values ​​of c-IL-2 and cat-(X-IL-2) for binding to IL-2Rα were D In 10 -9 M level, K binding to IL-2Rβ D In 10 -7 M level.

[0017] Figure 5This is an in vitro cell differentiation test for IL-2 topological modification drugs in peripheral blood of patients with Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). The increase and inhibition of Treg, Tfh, Th1, Th2, and Th17 cells in patients with SLE, RA, and Sjögren's syndrome after treatment with different topological drugs indicate that c-IL-2 and cat-(X-IL-2) can activate Treg cells at a high level and inhibit Tfh and Th1 cells in the above patients.

[0018] Figure 6 The immune response of IL-2 topological modification drugs in the spontaneous mouse model of Sjögren's syndrome was tested. The test showed that c-IL-2 and cat-(X-IL-2) had a significant upregulation effect on immune regulatory Treg.

[0019] Figure 7 This is an evaluation of the effectiveness of IL-2 topological modifying drugs in an animal model of Sjögren's syndrome. The figure shows the salivary flow rate of mice after treatment. The test shows that the salivary flow rate of mice increased significantly after injection of c-IL-2 and was the same as that of the WT group (IL-2). The salivary flow rate of the cat-(X-IL-2) group showed an upward trend but there was no significant difference.

[0020] Figure 8 The immune response of IL-2 topological modification drugs in the animal model of systemic lupus erythematosus. c-IL-2 and cat-(X-IL-2) have a significant upregulation effect on immune-regulated Tregs, and the proliferation of lymph node Treg cells induced by them in mice is significantly higher than that of the WT group (IL-2), and the inhibition of germinal center B cell proliferation is the same as that of the WT group.

[0021] Fig. 9 HE staining of an autoimmune disease mouse model, in which systemic lupus erythematosus mice were stimulated with two topological modification drugs, IL-2, and PBS. The detection found that the inflammatory accumulation of c-IL-2 and cat-(X-IL-2) was significantly lower than that of the blank group (PBS), and was not much different from the WT group (IL-2).

[0022] Fig.10 The ANA level after treatment. The test results of c-IL-2 and cat-(X-IL-2) treated mice with systemic lupus erythematosus showed that the ANA level of mice injected with c-IL-2 and cat-(X-IL-2) was significantly lower than that of the blank group (PBS).

[0023] Fig.11This is an evaluation of the effectiveness of IL-2 topological modifying drugs in an animal model of systemic lupus erythematosus. The figure shows the amount of urine protein in mice after treatment. After drug stimulation, the urine protein in the c-IL-2 and cat-(X-IL-2) groups of mice was significantly reduced, and was significantly lower than that in the WT group (IL-2).

[0024] Fig.12 To evaluate the toxicity of topo IL-2 to MRL / lpr mice. After drug stimulation, the mice showed no signs of pulmonary edema, and all levels were within the normal range, indicating that topo IL-2 had no obvious toxicity.

[0025] Fig.13 To evaluate the effectiveness of IL-2 topomodifiers in an animal model of collagen-induced arthritis. Mice were stimulated with two topomodifiers, IL-2, and PBS. The severity of arthritis in mice was scored as follows: 0 = no redness or swelling; 1 = swelling of the little toe joint; 2 = swelling of the toe joint and tissue; 3 = swelling of the paw below the ankle joint; 4 = swelling of the entire paw including the ankle joint. The figure shows that the severity of arthritis in mice in the c-IL-2 and cat-(X-IL-2) groups was significantly reduced, and was significantly lower than that in the WT group.

[0026] Fig.14 The immune response of IL-2 topological modification drugs in the animal model of rheumatoid arthritis. The test showed that the lymph node Treg cells of the experimental group injected with c-IL-2 and cat-(X-IL-2) were significantly higher than those of the PBS group, and slightly higher than those of the WT group (IL-2); the spleen Treg cells were also significantly higher than those of the PBS group; the lymph node Th1, Th2, and Th17 cells of the experimental group injected with c-IL-2 and cat-(X-IL-2) were significantly lower than those of the PBS group, and the lymph node Th2 cells of the experimental group injected with c-IL-2 and cat-(X-IL-2) were significantly lower than those of the WT group. DETAILED DESCRIPTION

[0027] The following examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.

[0028] Example 1. Preparation of cyclic and catenane interleukin-2

[0029] According to the crystal structure of IL-2, the present invention fuses the C-terminal (IntC) and N-terminal (IntN) parts of the isolated intein at both ends of IL-2 to obtain the IntC-IL-2-IntN recombinant plasmid, such as Figure 1 As shown in (A); p53dim (X) was inserted into the above plasmid to obtain the IntC-X-IL-2-IntN recombinant plasmid, as shown in Figure 1As shown in (B). The expression vectors of both are pET15b. The above expression plasmids with ampicillin resistance were transformed into Escherichia coli Origami (DE3), and the positive strains were screened out by ampicillin resistance plates. The obtained positive expression strains were cultured in 2×YT medium containing 100μg / mL ampicillin at 37°C for 12 hours, inoculated and expanded until the OD of the bacterial solution reached 0.6-0.8, IPTG was added to a final concentration of 0.3mM, and the bacteria were collected after inducing expression at 16°C for 12 hours. The bacteria were resuspended in lysis buffer, treated with a cell disruptor, and then centrifuged at high speed to remove cell debris. Purification was carried out using Ni-NTA affinity chromatography, first washed thoroughly with rinse buffer, and then eluted with elution buffer to obtain preliminary purified c-IL-2 and cat-(X-IL-2) samples. The products were purified and characterized by size exclusion chromatography, and the molecular weight and secondary structure of the purified samples were characterized by LC-MS and circular dichroism, as shown Figure 2 shown.

[0030] The amino acid sequence of c-IL-2 (148aa) (SEQ ID No: 1) is as follows:

[0031] CFNGGHHHHHHEL APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKH LQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIIST LT GT (the underlined part is the amino acid sequence of wild-type interleukin-2)

[0032] cat-(X-IL2)(388aa) is composed of two identical loops, and the amino acid sequence of each loop (SEQ ID No: 2) is as follows: (The italic part is the p53dim sequence, and the underlined part is the wild-type interleukin-2 sequence)

[0033] Example 2: Characterization of the half-life of topological IL-2 and its affinity to receptors

[0034] Six-week-old female KM mice were randomly divided into three groups (n = 5), and each group was injected with a dose of 60 μg IL-2 / kg body weight. WT group IL-2 (Hingil), c-IL-2, cat-(X-IL-2) (dissolved in PBS solution) were injected into the mouse peritoneal cavity. Peripheral blood samples (200 μL each time) were taken from the eye socket at 30 minutes, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours and 72 hours. The concentration of IL-2 was quantified using a human IL-2 ELISA kit (Neobioscience), as shown in Figure 2. Figure 3 As shown, the half-life of topological IL-2 was significantly improved compared with the wild type.

[0035] BLI characterization was performed using a streptavidin probe. Samples of WT group IL-2 (Hingil), c-IL-2, and cat-(X-IL-2) were diluted to 1000, 330, 110, 37, and 12 nM (IL-2) with buffer (PBS, 0.05% Tween-20, 0.5% BSA). The results are shown in Figure 4 As shown, the affinity of topological IL-2 to the receptor is in the same order of magnitude as that of wild-type (the K values ​​of IL-2 binding to IL-2Rα and IL-2β are D 6.58 nM and 129 nM respectively, reference Zhang, B. et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat. Biomed. Eng. 5, 1288-1305, doi: 10.1038 / s41551-021-00797-8 (2021)).

[0036] Example 3: IL-2 stimulation experiment of human peripheral blood PBMC

[0037] Peripheral blood was collected from patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren's syndrome (SS), and human peripheral blood mononuclear cells (PBMCs) were separated and stimulated with the test samples in vitro for 72 hours, and flow cytometry staining was performed using fluorescent antibodies: anti-CD3-AF700, anti-CD4-FITC, anti-CCR6-BV650, anti-CXCR3-PECF594, anti-CXCR5-AF647, anti-PD-1-PE-cy7, anti-CD3-PerCP, anti-CD127-BV605, and anti-CD25-APC. Detection of cell typing: Treg (CD3+CD4+CD25+CD127-), Tfh (CD3+CD4+CXCR5+PD-1+), Th1 (CD3+CD4+CCR6-CXCR3+), Th2 (CD3+CD4+CCR6-CXCR3-) and Th17 (CD3+CD4+CCR6+CXCR3-) results are as follows Figure 5 As shown, it indicates that c-IL-2 and cat-(X-IL-2) can activate Treg cells at a higher level and inhibit Tfh and Th1 cells in patients.

[0038] Example 4: Activity experiment of topological IL-2 in mice

[0039] (1) Sjögren's syndrome

[0040] Specific pathogen-free (SPF) 6-8 week old NOD female mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. and were housed in the SPF environment of the animal laboratory of Peking University People's Hospital. The experiment was conducted after one week of adaptive feeding. The treatment involved long-term administration. The WT group (IL-2) was administered three times a week for a total of one month; the c-IL-2 and cat-(X-IL-2) groups were administered once a week for a total of one month. The mice were given 15-minute salivary flow rate measurements before and after administration. After one month of administration, the spleen and lymph node cells were isolated from the mice for multicolor flow cytometry. The results showed that the injection of c-IL-2 and cat-(X-IL-2) can significantly promote the proliferation of Treg cells in the spleen and lymph nodes of mice, and have a certain inhibitory effect on germinal center B cells, such as Figure 6 The salivary flow rate of mice after treatment showed that the salivary flow rate of mice after c-IL-2 was significantly increased and was the same as that of the WT group (IL-2), and the salivary flow rate of the cat-(X-IL-2) group showed an upward trend but no significant difference ( Figure 7 )

[0041] (2) Systemic lupus erythematosus

[0042] Specific pathogen-free (SPF) 6-8-week-old C57 female mice purchased from Beijing Huafukang Biotechnology Co., Ltd. were all fostered in the SPF environment of the animal laboratory of Peking University People's Hospital. Modeling experiments were performed after 1 week of adaptive feeding. Modeling method: 1.25 mg of 5% IMQ cream was applied to the right ear skin of mice, once every other day, for 6 consecutive weeks. At the end of the 6th week of administration, the content of anti-double-stranded DNA (ds-DNA) antibodies in mouse serum was detected by enzyme-linked immunosorbent assay.

[0043] The treatment involved long-term administration. The WT group (IL-2) was administered three times a week for a total of 2 months; the c-IL-2 and cat-(X-IL-2) groups were administered once a week for a total of 2 months. Mouse serum was collected for biochemical testing, and liver, lung, heart, brain and other tissues were collected for pathological testing. Immunogenicity is one of the key factors affecting the effect of long-term administration of protein drugs. Therefore, the inventors evaluated the immunogenicity of WT IL-2, c-IL-2 and cat-(X-IL-2) in long-term administration. The results showed that c-IL-2 and cat-(X-IL-2) had high immunogenicity, and their induction of lymph node Treg cell proliferation in mice was significantly higher than that of the WT group, and the inhibition of germinal center B cell proliferation was on par with the WT group. Figure 8As shown. It proves that c-IL-2 and cat-(X-IL-2) have high immunogenicity in long-term administration. HE staining of the mouse model further found that the inflammatory aggregation of c-IL-2 and cat-(X-IL-2) was significantly lower than that of the blank group (PBS), and was not much different from the WT group (IL-2) ( Fig. 9 ). In addition, after treatment, it was found that the antinuclear antibody (ANA) content in mice injected with c-IL-2 and cat-(X-IL-2) was significantly lower than that in the blank group (PBS), such as Fig.10 shown. Fig.11 It was further shown that the urine protein in mice after treatment was significantly lower than that in the WT group. Fig.12 It was shown that topological IL-2 had no obvious physiological toxicity.

[0044] (3) Rheumatoid arthritis

[0045] Specific pathogen-free (SPF) 6-8-week-old DBA / 1 male mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. and were housed in the SPF environment of the animal laboratory of Peking University People's Hospital. Modeling experiments were performed after one week of adaptive feeding. Modeling method: Bovine Type II Collagen (C II) was dissolved with 100 mmol / L glacial acetic acid at 4°C overnight, mixed with Complete Freund's Adjuvant (CFA) at a volume ratio of 1:1, and fully emulsified. Subcutaneous injections were performed at two points at the base of the mouse tail, each containing 100 μg of C II emulsion; on the 21st day after the first immunization, C II and incomplete Freund's Adjuvant (IFA) were fully emulsified at a volume ratio of 1:1, and an emulsion containing 100 μg of C II was subcutaneously injected at the base of the mouse tail to complete the induction of collagen-induced arthritis (CIA) model. Six days after the second immunization, the mice gradually became ill, reaching a peak on the 14th day, and thus CIA mice were obtained.

[0046] The treatment involved long-term administration, WT group (IL-2) was administered 3 times a week for 2 months; c-IL-2 and cat-(X-IL-2) groups were administered once a week for 2 months. The severity of arthritis in mice was scored every other day: 0 = no redness or swelling; 1 = swelling of the little toe joint; 2 = swelling of the toe joint and tissue; 3 = swelling of the paw below the ankle joint; 4 = swelling of the entire paw including the ankle joint ( Fig.13 ). Two months after administration, spleen and lymph node cells were isolated from mice for multicolor flow cytometry. Fig.14As shown, the results showed that the Treg cells in the lymph nodes of the experimental group injected with c-IL-2 and cat-(X-IL-2) were significantly higher than those in the PBS group, and slightly higher than those in the WT group; the Treg cells in the spleen were also significantly higher than those in the PBS group. The Th1, Th2, and Th17 cells in the lymph nodes of the experimental group injected with c-IL-2 and cat-(X-IL-2) were significantly lower than those in the PBS group, and the Th2 cells in the lymph nodes of the experimental group injected with c-IL-2 and cat-(X-IL-2) were significantly lower than those in the WT group, and the occurrence and development of arthritis can be effectively prevented and treated.

Claims

1. An interleukin-2 topological modification protein, which is cyclic interleukin-2 or catenane interleukin-2, in, The cyclic interleukin-2 is an interleukin-2 with a ring structure formed by connecting the N-terminus and the C-terminus of interleukin-2; the catenane interleukin-2 is an interleukin-2 dimer with a catenane structure obtained by fusion expression of interleukin-2 and a protein entanglement motif capable of forming a dimer, and forming an intermolecular entanglement dimer and a closed ring structure through the protein entanglement motif, wherein the protein entanglement motif is a tumor suppressor factor p53dim.

2. The interleukin-2 topologically modified protein according to claim 1, It is characterized in that The amino acid sequence of the cyclic interleukin-2 is shown in SEQ ID No: 1 in the sequence listing.

3. The interleukin-2 topologically modified protein according to claim 1, It is characterized in that The catenane interleukin-2 is composed of two identical rings, and the amino acid sequence of each ring is shown in SEQ ID No: 2 in the sequence list.

4. Use of the interleukin-2 topologically modified protein according to any one of claims 1 to 3 in the preparation of a medicament for treating an immune-related disease, wherein the immune-related disease is an autoimmune disease, an immunodeficiency disease, a tumor or a viral infection.

5. The use according to claim 4, It is characterized in that The autoimmune diseases include systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, organ transplant rejection, graft-versus-host disease, dermatomyositis, and multiple sclerosis.

6. A pharmaceutical composition comprising the interleukin-2 topologically modified protein according to any one of claims 1 to 3.